Why the equation changed in 2021
The original CKD-EPI equation, published in 2009, included a multiplier of 1.159 for patients reported as Black. The justification at the time was statistical: Black participants in the development dataset had slightly higher creatinine on average, presumed to reflect higher muscle mass. The consequence was that Black patients were assigned a higher eGFR for the same creatinine value, which often delayed referral for nephrology care, transplant listing, and medication adjustments.
In 2021, a multidisciplinary task force — the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease — recommended replacing the 2009 equation with a race-free version. The new equation, published by Inker and colleagues in NEJM, performs comparably well across populations without using race as an input. It is now the standard recommendation across US clinical labs and is endorsed by both the National Kidney Foundation and the American Society of Nephrology.
Limits of any creatinine-based eGFR
Creatinine is produced by muscle and cleared by the kidneys, so anything that disturbs the relationship between muscle mass and kidney function will throw the estimate off. Body builders may have falsely low eGFR; people with very low muscle mass (e.g., cachexia, paralysis) may have falsely high eGFR. In those cases your nephrologist may order a cystatin C-based eGFR (which uses a different filtered marker) or a 24-hour urine collection.
Source: Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737-1749.